Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2015

Open Access 01-12-2015 | Original investigation

Cross-sectional analysis of serum calcium levels for associations with left ventricular hypertrophy in normocalcemia individuals with type 2 diabetes

Authors: Junfeng Li, Nan Wu, Yintao Li, Kuanping Ye, Min He, Renming Hu

Published in: Cardiovascular Diabetology | Issue 1/2015

Login to get access

Abstract

Background

Left ventricular hypertrophy (LVH) is prevalent in patients with type 2 diabetes mellitus (T2DM). Recent studies show that an increase in albumin-adjusted serum calcium level is associated with an elevated risk of T2DM. We speculate that increased serum calcium levels in T2DM patients are related to LVH prevalence.

Methods

In this echocardiographic study, 833 normocalcemia and normophosphatemia patients with T2DM were enrolled. The associations between serum calcium and metabolic parameters, left ventricular mass index (LVMI), as well as the rate of LVH were examined using bivariate linear correlation, multivariate linear regression and logistic regression, respectively. The predictive performance of serum calcium for LVH was evaluated using the area under the receiver operating characteristic curve (AUC).

Results

Patients with LVH have significantly higher serum calcium than those without LVH. Serum calcium was positively associated with total cholesterol, triglycerides, low-density lipoprotein cholesterol, serum uric acid, HOMA-IR and fasting plasma glucose. Multivariate linear regression analysis demonstrated that serum calcium was independently associated with LVMI (p < 0.001). In comparison with patients in the lowest serum calcium quartile, the odds ratio (OR) for LVH in patients in the highest quartile was 2.909 (95% CI 1.792-4.720; p < 0.001). When serum calcium was analyzed as a continuous variable, per 1 mg/dl increase, the OR (95% CI) for LVH was [2.400 (1.552-3.713); p < 0.001]. Serum calcium can predict LVH (AUC = 0.617; 95% CI (0.577-0.656); p < 0.001).

Conclusions

Albumin-adjusted serum calcium is associated with an increased risk of LVH in patients with T2DM.
Literature
1.
Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med. 1992;327(14):998–1008.CrossRefPubMed
2.
Eguchi K, Boden-Albala B, Jin Z, Rundek T, Sacco RL, Homma S, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol. 2008;101(12):1787–91.CrossRefPubMedCentralPubMed
3.
Dawson A, Morris AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia. 2005;48(10):1971–9.CrossRefPubMed
4.
Bruno G, Giunti S, Bargero G, Ferrero S, Pagano G, Perin PC. Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: the Casale Monferrato Study. Diabet Med. 2004;21(8):823–8.CrossRefPubMed
5.
Nkum BC, Micah FB, Ankrah TC, Nyan O. Left ventricular hypertrophy and insulin resistance in adults from an urban community in The Gambia: cross-sectional study. PLoS One. 2014;9(4), e93606.CrossRefPubMedCentralPubMed
6.
Sato A, Tarnow L, Nielsen FS, Knudsen E, Parving HH. Left ventricular hypertrophy in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment. QJM. 2005;98(12):879–84.CrossRefPubMed
7.
Levy J. Abnormal cell calcium homeostasis in type 2 diabetes mellitus: a new look on old disease. Endocrine. 1999;10(1):1–6.CrossRefPubMed
8.
Lind L, Jakobsson S, Lithell H, Wengle B, Ljunghall S. Relation of serum calcium concentration to metabolic risk factors for cardiovascular disease. BMJ. 1988;297(6654):960–3.CrossRefPubMedCentralPubMed
9.
Kim MK, Kim G, Jang EH, Kwon HS, Baek KH, Oh KW, et al. Altered calcium homeostasis is correlated with the presence of metabolic syndrome and diabetes in middle-aged and elderly Korean subjects: the Chungju Metabolic Disease Cohort study (CMC study). Atherosclerosis. 2010;212(2):674–81.CrossRefPubMed
10.
Yamaguchi T, Kanazawa I, Takaoka S, Sugimoto T. Serum calcium is positively correlated with fasting plasma glucose and insulin resistance, independent of parathyroid hormone, in male patients with type 2 diabetes mellitus. Metab Clin Exp. 2011;60(9):1334–9.CrossRefPubMed
11.
Becerra-Tomas N, Estruch R, Bullo M, Casas R, Diaz-Lopez A, Basora J, et al. Increased serum calcium levels and risk of type 2 diabetes in individuals at high cardiovascular risk. Diabetes Care. 2014;37(11):3084–91.CrossRefPubMed
12.
Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM. Calcium and phosphate concentrations and future development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia. 2014;57(7):1366–74.CrossRefPubMed
13.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMed
14.
Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358–67.CrossRefPubMed
15.
Jafary FH. Devereux formula for left ventricular mass–be careful to use the right units of measurement. J Am Soc Echocardiogr. 2007;20(6):783.CrossRefPubMed
16.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63.CrossRefPubMed
17.
Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism. 2006;55(4):515–24.CrossRefPubMed
18.
Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011;34(6):e61–99.CrossRefPubMedCentralPubMed
19.
Wang Y, Mi J, Shan XY, Wang QJ, Ge KY. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes. 2007;31(1):177–88.CrossRef
20.
National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
21.
Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clinical endocrinology. 1999;50(3):321–8.CrossRefPubMed
22.
Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab. 1997;82(1):106–12.CrossRefPubMed
23.
Galetta F, Cupisti A, Franzoni F, Femia FR, Rossi M, Barsotti G, et al. Left ventricular function and calcium phosphate plasma levels in uraemic patients. J Intern Med. 2005;258(4):378–84.CrossRefPubMed
24.
Strozecki P, Adamowicz A, Nartowicz E, Odrowaz-Sypniewska G, Wlodarczyk Z, Manitius J. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail. 2001;23(1):115–26.CrossRefPubMed
25.
Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease. Clin Exp Nephrol. 2013;17(5):730–42.CrossRefPubMedCentralPubMed
26.
Nappi SE, Saha HH, Virtanen VK, Mustonen JT, Pasternack AI. Hemodialysis with high-calcium dialysate impairs cardiac relaxation. Kidney Int. 1999;55(3):1091–6.CrossRefPubMed
27.
Virtanen VK, Saha HH, Groundstroem KW, Seppala ES, Pasternack AI. Calcium infusion and left ventricular diastolic function in patients with chronic renal failure. Nephrol Dial Transplant. 1998;13(2):384–8.CrossRefPubMed
28.
Toussaint N, Cooney P, Kerr PG. Review of dialysate calcium concentration in hemodialysis. Hemodial Int. 2006;10(4):326–37.CrossRefPubMed
29.
Devereux RB, Pickering TG, Harshfield GA, Kleinert HD, Denby L, Clark L, et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation. 1983;68(3):470–6.CrossRefPubMed
30.
Waldum B, Os I. The cardiorenal syndrome: what the cardiologist needs to know. Cardiology. 2013;126(3):175–86.CrossRefPubMed
31.
de Simone G, Izzo R, De Luca N, Gerdts E. Left ventricular geometry in obesity: Is it what we expect? Nutr Metab Cardiovasc Dis. 2013;23(10):905–12.CrossRefPubMed
32.
de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A, et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens. 2002;20(2):323–31.CrossRefPubMed
33.
Sundstrom J, Lind L, Vessby B, Andren B, Aro A, Lithell H. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation. 2001;103(6):836–41.CrossRefPubMed
34.
Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, et al. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care. 2003;26(10):2764–9.CrossRefPubMed
35.
Franzini L, Ardigo D, Cavalot F, Miccoli R, Rivellese AA, Trovati M, et al. Women show worse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND.IT Study Group of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis. 2013;23(3):235–41.CrossRefPubMed
36.
Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, et al. Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. J Intern Med. 2013;274(2):176–91.CrossRefPubMed
37.
Tadic MV, Ivanovic BA, Petrovic M, Celic V, Neskovic A. Gender influence on left ventricular structure and function in metabolic syndrome. Are women at greater risk? J Clin Ultrasound. 2013;41(9):538–45.CrossRefPubMed
38.
Shigematsu Y, Norimatsu S, Ohtsuka T, Okayama H, Higaki J. Sex-related differences in the relations of insulin resistance and obesity to left ventricular hypertrophy in Japanese hypertensive patients. Hypertens Res. 2006;29(7):499–504.CrossRefPubMed
39.
Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F, Siepi D, et al. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension. 2006;47(5):881–6.CrossRefPubMed
40.
Nicolini E, Martegani G, Maresca AM, Marchesi C, Dentali F, Lazzarini A, et al. Left ventricular remodeling in patients with metabolic syndrome: influence of gender. Nutr Metab Cardiovasc Dis. 2013;23(8):771–5.CrossRefPubMed
41.
Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of “syndrome X”. Am J Hypertens. 1993;6(4):123S–34S.PubMed
42.
Resnick LM. Calcium metabolism in hypertension and allied metabolic disorders. Diabetes Care. 1991;14(6):505–20.CrossRefPubMed
43.
Sun G, Vasdev S, Martin GR, Gadag V, Zhang H. Altered calcium homeostasis is correlated with abnormalities of fasting serum glucose, insulin resistance, and beta-cell function in the Newfoundland population. Diabetes. 2005;54(11):3336–9.CrossRefPubMed
44.
Hagstrom E, Hellman P, Lundgren E, Lind L, Arnlov J. Serum calcium is independently associated with insulin sensitivity measured with euglycaemic-hyperinsulinaemic clamp in a community-based cohort. Diabetologia. 2007;50(2):317–24.CrossRefPubMed
45.
Vernooij JW, Cramer MJ, Visseren FL, Korndewal MJ, Bots ML, Meijs MF, et al. Relation between abdominal obesity, insulin resistance and left ventricular hypertrophy diagnosed by electrocardiogram and magnetic resonance imaging in hypertensive patients. Am J Cardiol. 2012;110(2):227–33.CrossRefPubMed
46.
Lind L, Andersson PE, Andren B, Hanni A, Lithell HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens. 1995;13(4):433–8.CrossRefPubMed
47.
Galvan AQ, Galetta F, Natali A, Muscelli E, Sironi AM, Cini G, et al. Insulin resistance and hyperinsulinemia: No independent relation to left ventricular mass in humans. Circulation. 2000;102(18):2233–8.CrossRefPubMed
48.
Patel VB, Vacek JL, Graves L, Bhattacharya RK. Calcium affects on vascular endpoints. Nutr Metab. 2012;9:24.CrossRef
49.
Saltevo J, Niskanen L, Kautiainen H, Teittinen J, Oksa H, Korpi-Hyovalti E, et al. Serum calcium level is associated with metabolic syndrome in the general population: FIN-D2D study. Eur J Endocrinol. 2011;165(3):429–34.CrossRefPubMed
50.
Wang S, Hou X, Liu Y, Lu H, Wei L, Bao Y, et al. Serum electrolyte levels in relation to macrovascular complications in Chinese patients with diabetes mellitus. Cardiovasc Diabetol. 2013;12:146.CrossRefPubMedCentralPubMed
51.
Mitsuhashi H, Yatsuya H, Matsushita K, Zhang H, Otsuka R, Muramatsu T, et al. Uric acid and left ventricular hypertrophy in Japanese men. Circ J. 2009;73(4):667–72.CrossRefPubMed
52.
Ichikawa R, Daimon M, Miyazaki T, Kawata T, Miyazaki S, Maruyama M, et al. Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2013;12:38.CrossRefPubMedCentralPubMed
53.
Klemmer PJ. Calcium loading, calcium accumulation, and associated cardiovascular risks in dialysis patients. Blood Purif. 2005;23 Suppl 1:12–9.CrossRefPubMed
54.
Barry SP, Davidson SM, Townsend PA. Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol. 2008;40(10):2023–39.CrossRefPubMed
55.
Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93(2):215–28.CrossRefPubMed
56.
Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation. 2010;122(25):2727–35.CrossRefPubMed
57.
Helvaci A, Copur B, Adas M. Correlation between Left Ventricular Mass Index and Calcium Metabolism in Patients with Essential Hypertension. Balkan Med J. 2013;30(1):85–9.CrossRefPubMedCentralPubMed
58.
Hagstrom E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33–9.CrossRefPubMed
59.
Lind L, Skarfors E, Berglund L, Lithell H, Ljunghall S. Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol. 1997;50(8):967–73.CrossRefPubMed
60.
Leifsson BG, Ahren B. Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab. 1996;81(6):2149–53.PubMed
61.
Renkema KY, Alexander RT, Bindels RJ, Hoenderop JG. Calcium and phosphate homeostasis: concerted interplay of new regulators. Ann Med. 2008;40(2):82–91.CrossRefPubMed
62.
Metadata
Title
Cross-sectional analysis of serum calcium levels for associations with left ventricular hypertrophy in normocalcemia individuals with type 2 diabetes
Authors
Junfeng Li
Nan Wu
Yintao Li
Kuanping Ye
Min He
Renming Hu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2015
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-015-0200-9

Other articles of this Issue 1/2015

Cardiovascular Diabetology 1/2015 Go to the issue

Original investigation

Association of obesity and long-term mortality in patients with acute myocardial infarction with and without diabetes mellitus: results from the MONICA/KORA myocardial infarction registry

Original investigation

Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis

Original investigation

Plasma leptin level is associated with cardiac autonomic dysfunction in patients with type 2 diabetes: HSCAA study

Original investigation

Interactive effects of a common γ-glutamyltransferase 1 variant and low high-density lipoprotein-cholesterol on diabetic macro- and micro-angiopathy

Original investigation

A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk

Original investigation

Adjustment of the GRACE score by HemoglobinA1c enables a more accurate prediction of long-term major adverse cardiac events in acute coronary syndrome without diabetes undergoing percutaneous coronary intervention
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits